OLMA - Olema Pharmaceuticals, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$40.33
DETAILS
HIGH:
$48.00
LOW:
$35.00
MEDIAN:
$38.00
CONSENSUS:
$40.33
UPSIDE:
255.23%
About Olema Pharmaceuticals, Inc. (https://www.olema.com)
Olema Pharmaceuticals, Inc., a biopharmaceutical enterprise in the clinical development stage, is dedicated to discovering, advancing, and commercializing therapeutic solutions for women's oncology. Headquartered in San Francisco, California, the company was established in 2006 and rebranded from CombiThera, Inc. in March 2009. Its most promising investigational compound, OP-1250, an estrogen receptor (ER) antagonist and selective ER degrader, is presently undergoing Phase 1/2 clinical evaluations. This drug candidate is being assessed for its efficacy in managing recurrent, locally advanced, or metastatic breast cancer that expresses estrogen receptors but is negative for human epidermal growth factor receptor 2.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Sean Bohen | President, CEO, CFO & Director | 1967 | $1,176,990 USD |
| Shane William Charles Kovacs | Consultant | 1974 | $902,735 USD |
| Naseem Zojwalla | Chief Medical Officer | 1973 | $777,970 USD |
| Shawnte Mitchell | Chief Legal Officer & Corporate Secretary | 1978 | $664,750 USD |
| David C. Myles | Chief Scientific Officer | 1963 | $200,000 USD |
| Angelos Dovletoglou | Senior Vice President of CMC & Supply Chain | – | – |
| Courtney O'Konek | Vice President of Corporate Communications | – | – |
| Julie Dexter | Senior Vice President & Head of People | – | – |
| Kamesh Kuchimanchi | Senior Vice President of Regulatory Affairs & Quality Assurance | – | – |
| Mark Shilkrut | Senior Vice President of Clinical Development | – | – |
| Richard Hernandez | Senior Vice President of Clinical Development Operations | – | – |